Gamma delta (γδ) T cells exhibit potent anti‐Plasmodium activity but are also implicated in the immunopathology of malaria.
Information provided in recent, related papers has wide-ranging implications concerning, inter alia, the transmission of malaria, drug treatment, and eradication of the disease.
The present study gave the first molecular evidence of P. vivax in Nigeria in Duffy negative individuals.
Plasmodium vivax remains a global health problem and its ability to cause relapses and subpatent infections challenge control and elimination strategies.
Vector-borne diseases account for more than 17% of all infectious diseases, causing more than one million deaths annually.
Sexual-stage proteins have a distinct function in the mosquito vector during transmission and also represent targets for the development of malaria transmission-blocking vaccine.
It is important to consider comorbid conditions and immunosuppression when a patient with a benign form of malaria presents with severe manifestations.
The newly developed ASO assay is a reliable and rapid tool for large-scale CYP2D6 genotyping.
A pan-malaria MSP119 cross-reactive antibody response was observed in elutions of blood spots from two 20–30 years old Mozambique donors. The antibody response from one of these two donors had low avidity and skewed almost entirely to the IgG3 subclass.
The findings support that the intake of PQ during 14 days of treatment against vivax malaria is safe in patients with a class III variant of G6PDd. In view of the new national regulations in the shortened treatment of vivax malaria for 7 days, it is advisable to be alert of potential cases of severe haemolysis that could occur among G6PD deficient hemizygous males with a class II mutation such as the Santamaria variant, previously reported in the country.